Capital Research Global Investors’s Sarepta Therapeutics SRPT Stock Holding History

Capital Research Global Investors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-557,461	Closed	-$67.6M	–	427
2023 Q3	$67.6M	Buy	557,461 +78	+0%	+$8.82K	0.02%	304
2023 Q2	$63.8M	Buy	557,383 +291,442	+110%	+$37.6M	0.02%	313
2023 Q1	$36.7M	Buy	+265,941	New	+$34.5M	0.01%	343
2021 Q4	–	Sell	-2,542,191	Closed	-$235M	–	464
2021 Q3	$235M	Sell	2,542,191 -2,208,578	-46%	-$170M	0.05%	234
2021 Q2	$369M	Sell	4,750,769 -3,276,134	-41%	-$248M	0.09%	196
2021 Q1	$598M	Buy	8,026,903 +290,155	+4%	+$26.8M	0.15%	139
2020 Q4	$1.32B	Buy	7,736,748 +1,025,424	+15%	+$152M	0.34%	74
2020 Q3	$942M	Buy	6,711,324 +2,006,643	+43%	+$305M	0.28%	83
2020 Q2	$754M	Buy	4,704,681 +829,723	+21%	+$113M	0.24%	95
2020 Q1	$379M	Buy	3,874,958 +1,465,905	+61%	+$168M	0.15%	128
2019 Q4	$311M	Buy	+2,409,053	New	+$243M	0.09%	177

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors's SRPT Position: Q4 2023 in Review

Capital Research Global Investors sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 557,461 shares — an estimated $67.6M sold.

Capital Research Global Investors first reported a position in SRPT in Q4 2019 and held it in 11 quarters. The position peaked at $1.32B in Q4 2020. 396 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

Capital Research Global Investors reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
Capital Research Global Investors sold 557,461 Sarepta Therapeutics shares in Q4 2023, an estimated $67.6M.
Capital Research Global Investors first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 11 quarters.
Capital Research Global Investors's Sarepta Therapeutics position peaked at $1.32B in Q4 2020.
396 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Capital Research Global Investors's 13F filing for Q4 2023, filed 13 Feb 2024.